聯邦制藥(03933.HK)治療糖尿病創新藥注射液獲藥監局受理臨床試驗註冊申請
聯邦制藥(03933.HK)公布,其全資附屬公司聯邦生物科技(珠海橫琴)有限公司自主研發的1類創新藥UBT251注射液關於成人2型糖尿病、體重管理和非酒精性脂肪肝/非酒精性脂肪肝炎適應症的臨床試驗註冊申請獲得中國藥監局受理及繳費通知書。現時公司為國內首間、全球第二間以化學合成多(月太)法製備的長效GLP-1(胰高血糖素樣(月太)-1)/GIP(葡萄糖依賴性促胰島素多(月太))/GCG(胰高血糖素)三激動劑申報臨床的企業。
集團預期,產品每周皮下注射給藥1次,針對2型糖尿病、超重/肥胖及非酒精性脂肪性肝炎等多種代謝紊亂疾病患者的治療有很好的獲益。現時,國內、外相同靶點藥物研發進展最快為剛宣布啟動臨床III期研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.